Fig. 3

A Heatmap of correlation between myeloid diversity and the activities of critical steps in anti-tumor immunity (colors represent the correlation coefficient, asterisks: p < 0.05, NS: non-significant). B–E Logistic regression of myeloid diversity to response rates of neoadjuvant therapies (AMG 386, ABT888/Carboplatin, Neratinib, and Pembrolizumab) from the I-SPY2 study (y axis represents the neoadjuvant responses of patients in the trials, x axis represents the normalized myeloid diversity index, OR: odds ratio calculated from the logistic regressions)